Immunis, Inc., a private biotech company developing novel secretome therapeutics for age-related diseases and immune dysfunction, announces that its esteemed Chairman, Dr. Hans Keirstead, will present at the 2024 BIO CEO & Investor Conference in New York City (February 26-27). Recognized as one of the largest investor conferences in the country, the event highlights established and emerging publicly traded and private biotech companies. The conference serves as a crucial platform for international investors, industry analysts, and biotechnology executives to engage in meaningful dialogue and explore future investments in the biomedical industry.

Dr. Keirstead will share Immunis’ commitment to generating groundbreaking, all-natural, all-human secretomes that improve patient outcomes for a variety of age and immune-related diseases. The recent milestones of Immunis’ ongoing Phase 1/2a clinical trial are sure to captivate audiences and bring light to the potential benefits of the investigational secretome product, IMMUNA, in reversing muscle atrophy in elderly participants.

“We are honored by the unique opportunity to share our vision and achievements with a distinguished audience of peers and investors who are as equally passionate about transforming promising discoveries into real-world solutions for patients,” says Dr. Keirstead. “We look forward to engaging with the community and fostering collaborations that continue to push the boundaries of the biotech industry.”

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com